Fri, November 29, 2024
[ Fri, Nov 29th 2024 ]: Thomas Matters
OUSA: A Solid Dividend Fund
[ Fri, Nov 29th 2024 ]: Thomas Matters
Stocks are rallying hard as the economy refuses to buckle. Will it last in 2025?
[ Fri, Nov 29th 2024 ]: Thomas Matters
Why Does Nvidia Make Up a Smaller Share of the Dow Jones Than the S&P 500 or Nasdaq-100?
[ Fri, Nov 29th 2024 ]: Thomas Matters
Will a Santa Rally bring festive cheer to investor portfolios this year?
[ Fri, Nov 29th 2024 ]: Thomas Matters
eToro: Tackling investing and trading with Premiership Rugby and Planet Rugby's official partner
[ Fri, Nov 29th 2024 ]: Thomas Matters
2 Outstanding Dividend King Stocks and 1 ETF to Buy for a Lifetime of Passive Income
[ Fri, Nov 29th 2024 ]: Thomas Matters
ChatGPT turns two: how has it impacted markets?
[ Fri, Nov 29th 2024 ]: Thomas Matters
Here's how I'm investing in dividend shares to aim for long-term wealth
[ Fri, Nov 29th 2024 ]: Thomas Matters
Stock Market vs. CDs: Where's The Best Place to Park Your Cash?
[ Fri, Nov 29th 2024 ]: Thomas Matters
The Fed is Losing the Inflation Battle. Investors Don't Care
[ Fri, Nov 29th 2024 ]: Thomas Matters
Prediction: Nvidia Stock Will Soar in 2025. Here's Why.
[ Fri, Nov 29th 2024 ]: Thomas Matters
This Billionaire Investor Has Owned Palantir Sinc .. Its IPO. He Just Dumped Nearly His Entire Stake.
[ Fri, Nov 29th 2024 ]: Thomas Matters
Does Warren Buffett Buy Growth Stocks? These 2 Top Buffett Stocks Are Crushing the Market.
[ Fri, Nov 29th 2024 ]: Thomas Matters
Dividends Are Never a Guarantee. These 3 Stocks Made Massive Cuts to Their Payouts This Year
[ Fri, Nov 29th 2024 ]: Thomas Matters
Can I transfer a cash ISA to a stocks and shares ISA?
[ Fri, Nov 29th 2024 ]: Thomas Matters
Should You Forget C3.ai and Buy These 2 AI Stocks Instead?
[ Fri, Nov 29th 2024 ]: Thomas Matters
Investors Looking for Stability Tap South Africa in Trump Era
[ Fri, Nov 29th 2024 ]: Thomas Matters
Scotia Global Asset Management announces fee reductions and year-end distribution estimates
[ Fri, Nov 29th 2024 ]: Thomas Matters
Active momentum funds gather steam as large fund houses enter the fray
[ Fri, Nov 29th 2024 ]: Thomas Matters
5 Mistakes to Avoid While Christmas Shopping at Costco This Year
[ Fri, Nov 29th 2024 ]: Thomas Matters
The Best Warren Buffett Stock to Buy With $500 Right Now
[ Fri, Nov 29th 2024 ]: Thomas Matters
7.7 million Australians are investing in ASX shares. Why aren't you?
[ Fri, Nov 29th 2024 ]: Thomas Matters
The Globe and Mail's 2024 Robo-Adviser Guide
[ Fri, Nov 29th 2024 ]: Thomas Matters
Bullish on Tesla, Apple, Nvidia? 4 ways to invest in international stocks
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ]: Thomas Matters
Sweden's Nalka Is Said to Pick Banks for Healthcare Unit IPO
[ Thu, Nov 28th 2024 ]: Thomas Matters
The best Vanguard ASX ETF to invest $2,000 in right now
[ Thu, Nov 28th 2024 ]: Thomas Matters
Stock market today: Wall Street wavers as Big Tech stocks fall
[ Thu, Nov 28th 2024 ]: Thomas Matters
Wall Street sees 'no alternative' to U.S. stocks in 2025. Here's why.
[ Thu, Nov 28th 2024 ]: Thomas Matters
Here's the Average Stock Market Return Over the L .. 10 Years, and What It Means for the Next 10 Years
[ Thu, Nov 28th 2024 ]: Thomas Matters
Why Is Structure Therapeutics Inc. (GPCR) Among t .. p and Coming Stocks to Buy According to Analysts?
[ Thu, Nov 28th 2024 ]: Thomas Matters
Stock market today: Losses for Big Tech pull US indexes lower
[ Thu, Nov 28th 2024 ]: Thomas Matters
What Happens To Your Money When A Mutual Fund Scheme Is Closed?
[ Thu, Nov 28th 2024 ]: Thomas Matters
Embecta upgraded to Buy from Neutral at BTIG
[ Thu, Nov 28th 2024 ]: Thomas Matters
MCAN Financial: Invested in Canadian Communities
[ Thu, Nov 28th 2024 ]: Thomas Matters
Al Harper named to Rocky Mountain Chocolate Factory board of directors
[ Thu, Nov 28th 2024 ]: Thomas Matters
Ripple's XRP could rally to $2.58 following a rise in whale buying activity
[ Thu, Nov 28th 2024 ]: Thomas Matters
Analysis-Australia's Hot Jobs Market Keeps Rate Cuts Out of Reach
[ Thu, Nov 28th 2024 ]: Thomas Matters
India's Defence Sector: Investing in Aatmanirbhar Push
[ Thu, Nov 28th 2024 ]: Thomas Matters
3 Market-Beating ETFs for Large-, Mid-, and Small-Cap Exposure
[ Thu, Nov 28th 2024 ]: Thomas Matters
How to Invest in Golden Goose Pre-IPO
[ Thu, Nov 28th 2024 ]: Thomas Matters
Digital infrastructure, interconnected Grid, & af .. t attractive investment destination: Piyush Goyal
[ Thu, Nov 28th 2024 ]: Thomas Matters
Canadian Dollar catches a break from selling pressure on Wednesday
[ Thu, Nov 28th 2024 ]: Thomas Matters
Adani Green Energy Says No Talks on New Financial Commitment With TotalEnergies
[ Thu, Nov 28th 2024 ]: Thomas Matters
OFP Funding Review 2024: : Everything You Need to Know Before Signing Up
[ Thu, Nov 28th 2024 ]: Thomas Matters
BMO ETFs: All-in-One Solutions for Simplified Investing
[ Thu, Nov 28th 2024 ]: Thomas Matters
Dow Jones Industrial Average ends Wednesday lower despite tapping record bid
[ Thu, Nov 28th 2024 ]: Thomas Matters
European Stocks off Two-Week Highs as Energy Stocks Weigh
[ Thu, Nov 28th 2024 ]: Thomas Matters
49-Year-Old Makes $5,180 a Month in Dividends Wit .. t Night' Portfolio - Top 10 Stocks You Can't Miss

Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
The article from The Globe and Mail discusses the investment potential of Eli Lilly and Company (LLY) stock, which has experienced a significant decline of over 20% from its peak. Despite this drop, the article suggests that now might be an opportune time to invest in Eli Lilly due to several positive factors. These include the company's robust pipeline of new drugs, particularly in high-demand areas like diabetes and oncology, with notable mentions of drugs like Mounjaro for diabetes and potential treatments for Alzheimer's. Additionally, Eli Lilly's financial health remains strong with consistent revenue growth and a promising outlook for future earnings. The article also highlights the company's strategic moves, such as acquisitions and partnerships, which could bolster its market position. However, it also notes potential risks like patent expirations and competition from other pharmaceutical giants. Overall, the piece frames Eli Lilly as a potentially undervalued stock with significant growth prospects, appealing to investors looking for long-term gains in the healthcare sector.

Read the Full The Globe and Mail Article at [ https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/29807676/down-more-than-20-from-its-high-is-now-the-time-to-buy-eli-lilly-stock/ ]